Received Mar 5, 2026
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| HPV4 | HPV (GARDASIL) | MERCK & CO. INC. | UNK | UNK | — |
| MNP | MENINGOCOCCAL CONJUGATE (PENMENVY) | GLAXOSMITHKLINE BIOLOGICALS | 1 | UNK | — |
Dizziness; This non-serious case was reported by a nurse via sales rep and described the occurrence of dizziness in a adult female patient who received Men ABCWY NVS (Penmenvy) for prophylaxis. Co-suspect products included HPV vaccine VLP rL1 4v (yeast) (Gardasil) for prophylaxis. On an unknown date, the patient received the 1st dose of Penmenvy and Gardasil. On an unknown date, an unknown time after receiving Penmenvy and an unknown time after receiving Gardasil, the patient experienced dizziness (Verbatim: Dizziness). The outcome of the dizziness was resolved. The reporter considered the dizziness to be related to Penmenvy. It was unknown if the reporter considered the dizziness to be related to Penmenvy Pre-Filled Syringe Device. The reporter considered the dizziness to be not reported if related to Gardasil. The company considered the dizziness to be related to Penmenvy. It was unknown if the company considered the dizziness to be related to Penmenvy Pre-Filled Syringe Device. The company considered the dizziness to be not reported if related to Gardasil. This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences. Additional Information: GSK Receipt Date: 26-FEB-2026 The patient was waiting to prevent syncope (per hospital system guidelines) & patient experienced dizziness. Patient also received Gardasil at same visit as well. The batch number was not provided and a request for this information has been made.; Sender's Comments: US-GSK-US2026027296:SAME REPORTER